Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Sell
10
SHNXY Quote, Financials, Valuation and Earnings
Last price:
$18.19
Seasonality move
:
0%
Day range:
$18.19 - $18.19
52-week range:
$18.19 - $18.19
Dividend yield:
2.12%
P/E ratio:
20.40x
P/S ratio:
1.09x
P/B ratio:
1.79x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$1.2B
Revenue:
$1.1B
EPS (TTM):
$0.89
Analysts' Opinion
-
Consensus RatingShandong Xinhua Pharmaceutical has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Shandong Xinhua Pharmaceutical has an estimated downside of -- from its current price of $18.19.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $18.19.
Fair Value
-
According to the consensus of 0 analysts, Shandong Xinhua Pharmaceutical has -- downside to fair value with a price target of -- per share.
SHNXY vs. S&P 500
-
Over the past 5 trading days, Shandong Xinhua Pharmaceutical has overperformed the S&P 500 by 0.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Shandong Xinhua Pharmaceutical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Shandong Xinhua Pharmaceutical has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Shandong Xinhua Pharmaceutical reported revenues of $279.6M.
Earnings Growth
-
Shandong Xinhua Pharmaceutical earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Shandong Xinhua Pharmaceutical reported earnings per share of $0.15.
Enterprise value:
1.3B
EV / Invested capital:
--
Price / LTM sales:
1.09x
EV / EBIT:
18.67x
EV / Revenue:
1.16x
PEG ratio (5yr expected):
5.55x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
18.67x
Gross Profit (TTM):
$290.4M
Return On Assets:
5.29%
Net Income Margin (TTM):
5.38%
Return On Equity:
9.11%
Return On Invested Capital:
7.07%
Operating Margin:
5.01%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.1B | $1.2B | $1.2B | $252.2M | $279.6M | |
| Gross Profit | $275.9M | $357.2M | $290.4M | $68.9M | $55.5M | |
| Operating Income | $69.7M | $93.4M | $81.1M | $15.5M | $14M | |
| EBITDA | $71.2M | $89.4M | $72M | $17.2M | $13.9M | |
| Diluted EPS | $0.82 | $1.05 | $0.89 | $0.25 | $0.15 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $379M | $416.3M | $486.2M | $414.8M | $517.6M | |
| Total Assets | $980.9M | $1.1B | $1.1B | $1.1B | $1.3B | |
| Current Liabilities | $310.1M | $371M | $452.1M | $299.5M | $385.5M | |
| Total Liabilities | $505.7M | $556.5M | $561.5M | $441.4M | $531.7M | |
| Total Equity | $475.2M | $554.5M | $588.5M | $644.3M | $726.7M | |
| Total Debt | $153.8M | $170.1M | $262.6M | $185.7M | $236.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$2.9M | -$10.8M | |
| Cash From Investing | -$35.6M | -$33.1M | -$37.9M | -$8.8M | -$6.2M | |
| Cash From Financing | $48.8M | -$103.2M | $19.9M | -$19.4M | $8.2M | |
| Free Cash Flow | -- | -- | -- | -$13.5M | -$18.2M | |
SHNXY
Sector
Market Cap
$1.2B
--
Price % of 52-Week High
100%
--
Dividend Yield
2.12%
--
Shareholder Yield
--
--
1-Year Price Total Return
--
--
Beta (5-Year)
--
--
Dividend yield:
2.12%
Annualized payout:
$0.00
Payout ratio:
50.96%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$18.19
200-day SMA
Sell
Level
$18.19
Bollinger Bands (100)
Sell
Level
18.19 - 18.19
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$18.19
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$18.19
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
100
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2051)
Buy
CA Score
(Annual)
Level (0.3344)
Buy
Beneish M-Score
(Annual)
Level (-2.4103)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.6927)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs which also generates key revenue, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics. Geographically, the company generates a majority of its revenue from China (including Hong Kong), America, Europe and others.
Stock Forecast FAQ
In the current month, SHNXY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SHNXY average analyst price target in the past 3 months is --.
-
Where Will Shandong Xinhua Pharmaceutical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Shandong Xinhua Pharmaceutical share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Shandong Xinhua Pharmaceutical?
Analysts are divided on their view about Shandong Xinhua Pharmaceutical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Shandong Xinhua Pharmaceutical is a Sell and believe this share price will rise from its current level to --.
-
What Is Shandong Xinhua Pharmaceutical's Price Target?
The price target for Shandong Xinhua Pharmaceutical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SHNXY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Shandong Xinhua Pharmaceutical is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SHNXY?
You can purchase shares of Shandong Xinhua Pharmaceutical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Shandong Xinhua Pharmaceutical shares.
-
What Is The Shandong Xinhua Pharmaceutical Share Price Today?
Shandong Xinhua Pharmaceutical was last trading at $18.19 per share. This represents the most recent stock quote for Shandong Xinhua Pharmaceutical. Yesterday, Shandong Xinhua Pharmaceutical closed at $18.19 per share.
-
How To Buy Shandong Xinhua Pharmaceutical Stock Online?
In order to purchase Shandong Xinhua Pharmaceutical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
